🔬 Corporate Updates & Partnerships

• Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
• OBIO® Paves the Way for Companies to Succeed in Canada as a Stepping Stone to New Global Markets

💊 Clinical Trials & Therapeutic Breakthroughs

• 4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis
• Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML
• Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of PTSD

🧬 Gene Therapy & Advanced Biotech Platforms

• AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial
• Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025

🧬 Personalized Medicine

• Elegen and Nutcracker Pilot Cell-Free Manufacturing Process for RNA-Based Personalized Cancer Therapeutics

#biotech #lifesciences #healthcareinnovation #leadership #drugdevelopment #clinicaltrials #biopharma #LinkedInNews #genetherapy #personalizedmedicine

💡 Follow the BioTech Weekly newsletter for more updates on biotech breakthroughs, regulatory milestones, and investment trends in life sciences.

Disclaimer: This podcast includes content generated with the help of large language models (LLM). Although care has been taken to ensure accuracy, LLMs can sometimes produce incorrect or misleading information. Listeners are advised to independently verify any details, provide feedback, and reach out.